# Forte Biosciences, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Forte Biosciences, Inc.). ## Overview Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing FB102, its lead product candidate, for immune-mediated diseases. The company has no approved products and no product revenue, so its value is tied primarily to advancing FB102 through preclinical and clinical development toward regulatory approval. ## Products & services • FB102 lead product candidate for immune-mediated diseases • Preclinical research and clinical development programs • Drug manufacturing and clinical supply management via third parties • Potential future collaborations, licenses, milestones, and royalties - **Lead product candidate: FB102** (0%) — The company’s main therapeutic asset under development for immune-mediated indications such as celiac disease and vitiligo. - **Preclinical and clinical development** (0%) — Research, trial execution, and data generation needed to advance FB102 through development milestones. - **Manufacturing and clinical supply** (0%) — Outsourced drug substance and drug product manufacturing, plus supply chain support for studies. - **Future partnering and licensing** (0%) — Potential collaboration, license, milestone, and royalty economics if the company partners assets. - FB102 lead product candidate for immune-mediated diseases - Preclinical research and clinical development programs - Drug manufacturing and clinical supply management via third parties - Potential future collaborations, licenses, milestones, and royalties ## Customers Forte does not currently sell approved products, so it has no commercial customer base today. Its future customers would likely be physicians, patients, and third-party payors in the immune-mediated disease markets if FB102 is approved and commercialized. In the near term, the company’s key external counterparties are CROs, CMOs, and other service providers that support development and manufacturing. - **Future physicians and patients** (primary) — Would use FB102 if approved for immune-mediated diseases such as celiac disease or vitiligo. - **Third-party payors** (secondary) — Would determine reimbursement and access if the product reaches commercialization. - **CROs and CMOs** (primary) — Provide outsourced trial execution and manufacturing services that enable development. - **Potential licensing or collaboration partners** (emerging) — Could provide funding, development support, or commercialization rights through deals. - Physicians and patients in celiac disease and vitiligo markets - Third-party payors that would influence adoption after approval - CROs that run preclinical and clinical studies - CMOs that manufacture clinical and future commercial supply - Potential licensing partners and collaborators ## Geography Forte is a U.S.-based company and its disclosures emphasize exposure to U.S. capital markets, FDA regulation, and domestic clinical development activity. The company also notes global macro and geopolitical risks, but it does not disclose meaningful country-level revenue because it has no product sales. Its operational footprint is therefore concentrated in the United States, with outsourced research and manufacturing potentially involving third parties in other regions. - Headquartered in the United States - Clinical and regulatory dependence on the FDA and U.S. capital markets - No disclosed product revenue by country - Outsourced CRO/CMO activity may extend beyond the U.S. - Global macro shocks can affect financing, supply, and trial timelines ## Strategy Forte’s strategy is to concentrate resources on FB102 after discontinuing FB-401, reflecting a narrower and more capital-efficient development focus. The company is prioritizing clinical progress, manufacturing readiness, and regulatory execution while preserving optionality for future collaborations or licensing if needed. Because it is early stage and capital constrained, execution speed and data quality are central to its competitive position. - **Advance FB102 through clinical development** (short-term) — The company’s prospects are highly dependent on FB102 succeeding in early-stage studies and later trials. - **Secure manufacturing and clinical supply** (short-term) — Drug supply and cGMP readiness are required to continue trials and prepare for any future commercialization. - **Raise additional capital or partner assets** (medium-term) — The company will need funding to continue development and may use collaborations to reduce dilution or share risk. - Focus capital and management on FB102 after stopping FB-401 - Advance clinical and preclinical work to generate proof-of-concept data - Use third-party CROs and CMOs to keep fixed costs lower - Preserve partnering and licensing optionality for funding or reach - Build regulatory and manufacturing readiness for eventual approval ## Risks Forte is a pre-revenue biotech with a single lead asset, so clinical failure, financing shortfalls, or regulatory setbacks could materially impair the business. Its reliance on third parties for trials and manufacturing, plus patent and market-acceptance risk, creates a high-risk development profile typical of early-stage drug companies. Public-market volatility, Nasdaq compliance, and internal control issues add additional financial and trading risk. - **Clinical development failure of FB102** [critical] — The company is almost entirely dependent on one lead candidate, and early data may not predict later-stage success. - **Financing risk and going-concern pressure** [critical] — The company has no product revenue and will need additional capital to continue development. - **Third-party manufacturing and trial execution risk** [high] — Forte relies on CROs and CMOs, so delays or quality issues can disrupt timelines and increase costs. - **Intellectual property and patent risk** [high] — Without strong patent protection, competitors could develop similar therapies and erode future value. - **Nasdaq compliance and stock volatility** [medium] — Prior bid-price noncompliance and volatile trading can reduce market access and investor confidence. - **Public health and macroeconomic disruption** [medium] — Inflation, rate pressure, geopolitical conflict, and epidemics can delay trials and make financing harder. - FB102 may fail in preclinical or clinical development - The company needs additional capital to fund operations - Reliance on CROs and CMOs can create execution and supply risk - Patent protection may be insufficient against competitors - Nasdaq bid-price or listing issues could hurt liquidity - Market volatility and internal control weaknesses could pressure valuation ## Accounting The most important accounting issue is that Forte expenses research and development as incurred, while clinical and manufacturing costs are estimated based on work completed by third parties. Because the company has no product revenue, quarterly results are driven mainly by trial activity, manufacturing spend, and cash interest income, which can create significant period-to-period volatility. Investors should also watch for capitalized advance payments, stock-based compensation, and any future impairment or financing-related accounting judgments as the company scales. - **Research and development expense recognition** — Can materially change reported operating loss from quarter to quarter - **Accruals for CRO and CMO services** — Affects R&D expense and accrued liabilities - **Capitalized advance payments** — Can shift expense recognition across reporting periods - **Cash and short-term investment income** — Can partially offset operating losses but is not core operating performance - R&D is expensed as incurred, so trial timing drives reported losses - CRO and CMO costs rely on completion estimates and can shift between periods - Non-refundable advance payments may be deferred and capitalized - No product revenue means results depend on expense timing and interest income - Future financing and equity issuance could affect dilution and expense recognition --- *Last updated: 2026-04-28T20:08:40.964187+00:00*